Live price temporarily unavailable.
Vaccinex (VCNX) is a Health Care company. Latest news and coverage below.
| FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $90.0K | $724.0K | $523.0K | $625.0K | $900.0K | $275.0K | $570.0K | $601.0K |
| Growth (year over year) | — | +704.4% | −27.8% | +19.5% | +44.0% | −69.4% | +107.3% | +5.4% |
| Gross profit | −$70.0K | −$309.0K | $324.0K | $623.0K | — | — | — | — |
| Gross margin | −77.8% | −42.7% | 62.0% | 99.7% | — | — | — | — |
| Operating income | −$21.1M | −$27.3M | −$32.0M | −$28.3M | −$22.5M | −$19.9M | −$22.9M | −$18.7M |
| Operating margin | −23448.9% | −3768.1% | −6121.4% | −4533.0% | −2498.9% | −7238.5% | −4014.9% | −3117.3% |
| Net income | −$18.7M | −$29.5M | −$31.9M | −$28.9M | −$22.4M | −$19.8M | −$20.3M | −$18.6M |
| Net margin | −20802.2% | −4077.1% | −6092.4% | −4616.2% | −2486.7% | −7205.5% | −3552.8% | −3100.5% |
| EPS (diluted) | −$4477.50 | −$1271.25 | −$555.75 | −$346.50 | −$11.70 | −$98.05 | −$43.68 | −$8.88 |
| Balance sheet | ||||||||
| Cash and equivalents | $4.18M | $5.62M | $2.78M | $10.6M | $8.59M | $6.39M | $1.53M | $1.11M |
| Total assets | $5.58M | $22.0M | $4.60M | $11.7M | $9.84M | $7.98M | $3.63M | $2.60M |
| Total liabilities | $7.35M | $6.69M | $6.88M | $14.3M | $2.43M | $2.78M | $5.94M | $5.08M |
| Long-term debt | — | — | — | $1.13M | $175.0K | $101.0K | $26.0K | $0 |
| Shareholders' equity | −$125.5M | −$8.62M | −$26.2M | −$26.6M | $7.41M | $5.19M | −$2.31M | −$2.49M |
| Cash flow | ||||||||
| Operating cash flow | −$21.4M | −$25.3M | −$30.7M | −$28.6M | −$25.3M | −$19.1M | −$21.4M | −$16.2M |
| Capital expenditure | $68.0K | $235.0K | $78.0K | $290.0K | $32.0K | $99.0K | $67.0K | $22.0K |
| Free cash flow | −$21.5M | −$25.5M | −$30.8M | −$28.9M | −$25.3M | −$19.2M | −$21.4M | −$16.2M |
| Q1 FY23Mar 2023 | Q2 FY23†Jun 2023 | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $550.0K | $0 | $20.0K | — | $104.0K | $232.0K | $52.0K | $213.0K |
| Growth (year over year) | — | — | −60.0% | — | −81.1% | — | +160.0% | — |
| Operating income | −$4.99M | −$7.08M | −$5.83M | — | −$5.07M | −$5.72M | −$4.55M | −$3.39M |
| Operating margin | −906.5% | — | −29170.0% | — | −4878.8% | −2466.4% | −8753.8% | −1590.1% |
| Net income | −$4.96M | −$7.06M | −$4.91M | — | −$3.90M | −$5.63M | −$5.73M | −$3.37M |
| Net margin | −902.2% | — | −24560.0% | — | −3747.1% | −2427.2% | −11023.1% | −1584.0% |
| EPS (diluted) | −$20.89 | −$24.54 | −$15.25 | — | −$2.94 | −$3.10 | −$2.83 | −$0.01 |
| Balance sheet | ||||||||
| Cash and equivalents | $3.32M | $1.91M | $127.0K | $1.53M | $2.97M | $233.0K | $2.91M | $1.11M |
| Total assets | $4.89M | $3.08M | $2.56M | $3.63M | $7.37M | $2.37M | $4.85M | $2.60M |
| Total liabilities | $2.50M | $3.51M | $6.43M | $5.94M | $4.71M | $5.23M | $6.17M | $5.08M |
| Long-term debt | $82.0K | $63.0K | $44.0K | $26.0K | $6.00K | — | — | $0 |
| Shareholders' equity | $2.40M | −$423.0K | −$3.87M | −$2.31M | $2.65M | −$2.86M | −$1.32M | −$2.49M |
| Cash flow | ||||||||
| Operating cash flow | −$5.04M | −$5.51M | −$3.10M | — | −$4.63M | −$4.42M | −$3.21M | −$3.93M |
| Capital expenditure | $49.0K | $0 | $18.0K | — | $0 | $14.0K | $8.00K | $0 |
| Free cash flow | −$5.09M | −$5.51M | −$3.11M | — | −$4.63M | −$4.43M | −$3.21M | −$3.93M |
From Vaccinex's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Vaccinex in our feed yet.